Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167891 | 0.87 | MMP13 (0.47) | MMP13SLC22A8ACHEHSP90AB1DDR1 | |
| SCHEMBL6700403 | 0.84 | MMP13 (0.48) | MMP13GRM2SLC22A8ACHETNF | |
| SCHEMBL6170469 | 0.84 | MMP13 (0.44) | MMP13SLC22A8ACHETNFHSP90AB1 | |
| SCHEMBL6176309 | 0.83 | MMP13 (0.47) | MMP13GRM2SLC22A8ACHETNF | |
| SCHEMBL6180680 | 0.82 | MMP13 (0.46) | MMP13SLC22A8ACHETNFHSP90AB1 | |
| SCHEMBL6175854 | 0.82 | MMP13 (0.46) | MMP13SLC22A8ACHETNFHSP90AB1 | |
| SCHEMBL6167249 | 0.82 | MMP13 (0.56) | MMP13SLC22A8ACHE | |
| SCHEMBL6178058 | 0.81 | MMP13 (0.49) | MMP13SLC22A8ACHEHSP90AB1DDR1 | |
| SCHEMBL6169541 | 0.81 | MMP13 (0.46) | MMP13SLC22A8TNF | |
| SCHEMBL6167628 | 0.80 | MMP13 (0.53) | MMP13SLC22A8DDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | MMP13 2/4885GRM2 3101/4885SLC22A8 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.